Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

Robert L. Wilensky(Hospital of the University of Pennsylvania), Yi Shi(Thomas Jefferson University), Emile R. Mohler(Hospital of the University of Pennsylvania), Damir Hamamdzic(Hospital of the University of Pennsylvania), Mark Burgert(GlaxoSmithKline (India)), Jun Li(CSL (United States)), Anthony D. Postle(Southampton General Hospital), Robert S. Fenning(Hospital of the University of Pennsylvania), James G. Bollinger(University of Washington), Bryan E. Hoffman(GlaxoSmithKline (India)), Daniel J. Pelchovitz(Hospital of the University of Pennsylvania), Jisheng Yang(Hospital of the University of Pennsylvania), Rosanna C. Mirabile(GlaxoSmithKline (India)), Christine L. Webb(GlaxoSmithKline (India)), LeFeng Zhang(Thomas Jefferson University), Ping Zhang(Thomas Jefferson University), Michael H. Gelb(University of Washington), Max Walker(GlaxoSmithKline (India)), Andrew Zalewski(GlaxoSmithKline (India)), Colin H. Macphee(GlaxoSmithKline (India))
Nature Medicine
September 21, 2008
Cited by 388Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis